Of patients with metastatic disease (n = 2997), 1.1% (n = 32) were identified to a pathogenic CDK12 alteration compared to 0.36% (n = 7) in patients with localized disease (n = 1937). This evidence concerns the gene CDK12 and metastatic neoplasm.